Stimuli-responsive systems for controlled drug delivery

Details Stimuli-responsive systems for controlled drug delivery Stimuli-responsive systems for controlled drug delivery

2009-03-31

2011-11-22

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Matrices

Reexamination Certificate

active

08062668

ABSTRACT:
A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

REFERENCES:
patent: 4348387 (1982-09-01), Brownlee et al.
patent: 5641515 (1997-06-01), Ramtoola et al.
patent: 5707644 (1998-01-01), Illum et al.
patent: 5814449 (1998-09-01), Schultz et al.
patent: 5830506 (1998-11-01), Taylor et al.
patent: 5902607 (1999-05-01), Taylor et al.
patent: 6063116 (2000-05-01), Kelleher
patent: 6221397 (2001-04-01), Russell-Jones et al.
patent: 6410053 (2002-06-01), Taylor
patent: 6454710 (2002-09-01), Ballerstadt et al.
patent: 6671527 (2003-12-01), Petersson et al.
patent: 0626862 (1994-12-01), None
patent: 0706401 (1996-04-01), None
patent: WO-9313803 (1993-07-01), None
patent: WO-9501186 (1995-01-01), None
Allen, et al., “Binding of Rat and Human Surfactant Proteins A and D to Aspergillus Fumigatus Conidia”,Infection and Immunity, 67(9): 4563-4569, 1999.
Armstron, et al., “Dextran-linked Isulin: a Soluble high molecular weight derivative with biological activity in vivo and in vitro”, Biochemical and Biophysical Research Communications, 1972, vol. 47, pp. 354-360.
Armstrong, et al., “Dextran-linked insulin: a soluble high molecular weight derivative with biological activity in vivo and in vitro”,Biochem. Biophys. Res. Commun. 47: 354, 1972.
Baudys, et al., “Extending Insulin Action in Vivo by Conjugation to Carboxymethyl Dextran”,Bioconjugate Chem. 9: 176-183, 1998.
De Jong, et al., “Physically Crosslinked Dextran Hydrogels by Stereocomplex Formation of Lactic Acid Oligomers: Degradation and Protein Release Behavior”,Journal of Controlled Release, 71: 261-275, 2001.
Dillman, et al., “Preclinical Trials with Combinations and Conju ates of T101 Monoclonal Antibody and Doxorubicin”,Cancer Research, 46: 4886-4891, 1986.
Dumestre-Perard, et al., “Evaluation and Clinical Interest of Mannan Binding Lectin Function in Human Plasma”,Molecular Immunology, 39: 465-473, 2002.
Eda, et al., “Characterization of Truncated Human Mannan-Binding Protein (MBP) Expressed inEscherichia coli”, Biosci. Biotechnol. Biochem. 62(7): 1326-1331, 1998.
Eda, et al., “Recombinant bovine conglutinin, lacking the N-terminal and collagenous domains, has less conglutination activity but is able to inhibit haemagglutination by influenza A virus”,Biochem J. 316:43-48, 1996.
Eda, et al., “Structure of a truncated human surfactant protein D is less effective in agglutinating bacteria than the native structure and fails to inhibit haemagglutination by influenza A virus”,Biochem J. 323:393-399, 1997.
Engel, et al., “The Crystal Structure of Dipeptidyl Peptidase IV (CD26) Reveals is Functional Regulation and Enzymatic Mechanism”,PNAS, 100(9): 5063-5068,2003.
Halestrap, et al., “The Proton Linked Monocarboxylate Transporter (MCT) Family: Structure, Function and Regulation”,Biochem. J., 343: 281-299, 1999.
Harada, et al., “Determinants for the Drug Release from T-0128, Camptothecin Analogue-Carboxymethyl Dextran Conjugate”,Journal of Controlled Release, 69: 399-412, 2000.
Huynh, et al., “Carboxymethylation of Dextran in Aqueous Alcohol as the First Step of the Preparation of Derivatized Dextrans”,Die Angewandte Makromolekulare Chemie, 254: 61-65, 1998.
International Search Report for PCT/US03/40393, Aug. 12, 2004.
Kagedal, et al., “Binding of Covalent Proteins to Polysaccharides by Cyanogen Bromide and Organic Cyanates. I. Preparation of Soluble Glycine-, Insulin- and Ampicillin-Dextran”,Acta Chemica Scandinavica, 25: 1855-1859, 1971.
Kim and Park, “Glucose-binding property of pegylated concanavalin A”,Pharmaceutical Research18: 794, 2001.
Kim and Park, “Modulated insulin delivery from glucose-sensitive hydrogel dosage forms”,J. Controlled Release77: 39, 2001.
Kim, et al., “Modulated insulin delivery from glucose-sensitive hydrogel dosage forms”, Jorunal of Controlled Release, 2001, vol. 77, pp. 39-47.
Looger, et al., “Computational Design of Receptor and Sensor Proteins with Novel Functions”,Nature, 423: 185-190, 2003.
Medina-Bolivar, et al., “A non-toxic lectin for antigen delivery of plant-based mucosal vaccines”,Vaccine21: 997-1005, 2003.
Mehvar, et al., “Molecular-Weight-Dependent Pharmacokinetics of Fluorescein-Labeled Dextrans in Rats”,Journal of Pharmaceutical Sciences, 81(9): 908-912, 1992.
Mislovicova, et al., “Neoglycoconjugates of Mannan with Bovine Serum Albumin and Their Interaction with Lectin Concanavalin A”,Bioconjugate Chem. 13: 136-142, 2002.
Mitra, et al., “Tumour Targeted Delivery of Encapsulated Dextran-Doxorubicin Conjugate Using Chitosan Nanoparticles as Carrier”,Journal of Controlled Release, 74: 317-323, 2001.
Ohya, et al., “Design of Macromolecular Prodrug of Cisplatin Using Dextran with Branched Galactose Units as Targeting Moieties to Hepatoma Cells”,Biomacromolecules, 2: 927-933, 2001.
Persson, et al., “Surfactant Protein D is a Divalent Cation-Dependent Carbohydrate-Binding Protein”,The Journal of Biological Chemistry, 265(10): 5755-5760, 1990.
Pickup, et al., “In vivo glucose sensing for diabetes managenet: progress towares non-invasive monitoring”, BMJ, 1999, vol. 319, p. 1289.
Sakamoto, et al., “Comparative Effects of Native Insulin and Insulin-Dextran Complexes on the Metabolism of Adipose Tissue”,Biochimica et Biophysica Acta, 498: 102-113, 1977.
Salins, et al., “A Novel Reagentless Sensing System for Measuring Glucose Based on the Galactose/Glucose-Binding Protein”,Analytical Biochemistry, 294: 19-26, 2001.
Sheriff, et al., “Human Mannose-Binding Protein Carbohydrate Recognition Domain Trimerizes Through a Triple α-Helical Coiled-Coil”,Structural Biology, 1(11): 789-794, 1994.
Sugahara, et al., “Characteristics of Tissue Distribution of Various Polysaccharides as Drug Carriers: Influences of Molecular Weight and Anionic Charge on Tumor Targeting”,Biol. Pharm. Bull. 24(5): 535-543, 2001.
Suzuki, et al., “Studies on the Mode of Action of Insulin: Properties and Biological Activity of an Insulin-Dextran Complex”, Edocrinology, 1972, vol. 90, No. 5, pp. 1220-1230.
Suzuki, et al., “Studies on the mode of insulin. properties and biological activity of an insulin-dextran complex”,Endocrinology90: 1220-1230, 1972.
Tanna, et al., “Covalent coupling of concanavalin A to a Carbopol 934P and 941P carrier in glucose-sensitive gels for delivery of insulin”,J. Pharm. Pharmacol. 11: 1461, 2002.
Thoma, et al., “Versatile Functionalization of Polylysine: Synthesis, Characterization, and Use of Neoglycoconjugates”,J. Am. Chem. Soc. 121: 5919-5929, 1999.
Ueno, et al., “Polyethylene glycol-modified pokeweed mitogen (PWM) as a potential non-immunogenic stimulator of lymphokine-activated killer cells”,J. Biomater. Sci. Polymer Edn. 7: 753, 1996.
Zion, et al., “Bio-Inspired Nanoscale Hybrid Systems”,Materials Research Society, Fall Meeting, Boston, MA, Dec. 2-4, 2002.

Affiliated with

Also associated with

Rating

Stimuli-responsive systems for controlled drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stimuli-responsive systems for controlled drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimuli-responsive systems for controlled drug delivery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4265726